0

The full content of Annals is available to subscribers

Subscribe/Learn More  >
Articles |

Prophylaxis against Gallstone Formation with Ursodeoxycholic Acid in Patients Participating in a Very-Low-Calorie Diet Program

Mitchell L. Shiffman, MD; Gordon D. Kaplan, PhD; Valerie Brinkman-Kaplan, MS, RD; and Florence F. Vickers*, PhD
[+] Article and Author Information

From the Medical College of Virginia, Richmond, Virginia. Health Management Resources, Boston, Massachusetts. Ciba-Geigy Pharmaceutical Company, Summit, New Jersey. Requests for Reprints: Mitchell L. Shiffman, MD, Hepatology Section, Medical College of Virginia, P.O. Box 980711, Richmond, VA 23298-0711. Note: During the course of this study, Dr. Shiffman was a paid consultant to Ciba-Geigy Pharmaceutical Company, Dr. Vickers was Associate Director and then Director of Research and Development for Ciba-Geigy, and Dr. Kaplan and Ms. Brinkman-Kaplan were employees of Health Management Resources. Acknowledgments: The authors thank Larry T.P. Stifler, PhD, of Health Management Resources, Inc., for support and assistance; Kathleen Crotty of Ciba-Geigy Corporation for supervising the preparation of our statistical report; and Sherri Holmes and Jennifer Coady for technical assistance with the bile analysis. Grant Support: By Ciba-Geigy Pharmaceutical Company and the National Institutes of Health first award DK43264 from the National Institutes of Digestive and Kidney Diseases.


Copyright ©2004 by the American College of Physicians


Ann Intern Med. 1995;122(12):899-905. doi:10.7326/0003-4819-122-12-199506150-00002
Text Size: A A A

Objective: To determine whether prophylactic treatment with ursodeoxycholic acid can prevent gallstone formation in persons participating in a very-low-calorie weight reduction diet program.

Design: Multicenter, double-blind, placebo-controlled, multidose clinical trial. Patients were treated with placebo or with 300 mg/d, 600 mg/d, or 1200 mg/d of ursodeoxycholic acid.

Setting: 31 Health Management Resources weight management centers.

Patients: 1004 patients were initially enrolled in a 16-week, 520-kcal/d, Health Management Resources liquid protein diet program. All patients had a body mass index of 38 kg/m2 or more and a normal gallbladder ultrasonogram before study entry. Bile analysis was done in 32 patients.

Measurements: Body weight and body mass index were measured before the diet was started and at 2-week intervals for 16 weeks. Gallbladder ultrasonography was done before enrollment and after 8 and 16 weeks of dieting. Bile was obtained by endoscopy and analyzed for cholesterol crystals and lipid levels.

Results: Mean body weight for all patients at the start of dieting was 128.2 kg ±23.2 kg; mean initial body mass index was 44.2 kg/m2 ±6.0 kg/m2. Gallstones developed in 28% (95% CI, 22% to 35%) of patients receiving placebo, in 8% (CI, 5% to 13%) of patients treated with 300 mg/d of ursodeoxycholic acid, in 3% (CI, 1% to 7%) of patients treated with 600 mg/d of ursodeoxycholic acid, and in 2% (CI, 0.5% to 5%) of patients treated with 1200 mg/d of ursodeoxycholic acid. The differences between patients receiving placebo and patients receiving ursodeoxycholic acid were statistically significant. The percentage of ursodeoxycholic acid in bile increased stepwise with increasing doses of ursodeoxycholic acid.

Conclusions: Ursodeoxycholic acid, 600 mg/d, is highly effective in preventing gallstone formation in patients having dietary-induced weight reduction.

For a listing of additional persons involved in the conduct of this study, see Appendix.

Figures

Grahic Jump Location
Figure 1.
Percentage of patients who developed gallstones during the diet program.

The fractions above each bar indicate the number of patients who developed gallstones in each group over the total number of patients in each group. Solid bars represent men; open bars represent women. Values for all doses of ursodeoxycholic acid in both men and women were significantly lower than those for placebo. For women, values for the 600 mg/d dose of ursodeoxycholic acid were significantly lower than those for the 300 mg/d dose. UDCA = ursodeoxycholic acid.

Grahic Jump Location
Grahic Jump Location
Figure 2.
Weight loss, body mass, and gallstone formation.Top.Bottom.

Fractions above each bar indicate the number of patients who developed gallstones in each group over the total number of patients in each group. Solid bars represent men; open bars represent women. Relation between the rate of weight loss and gallstone formation in patients treated with placebo. The stepwise increase seen in women was significant. No significant relation between rate of weight loss and gallstone formation was present in men. Relation between the percentage decrease in body mass index and gallstone formation in patients treated with placebo. BMI = body mass index.

Grahic Jump Location

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Related Point of Care
Topic Collections
PubMed Articles
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)